A recent suspension of sales of the drug Iclusig, used in the treatment of chronic myeloid leukemia and Philadelphia chromosome positive acute lymphoblastic leukemia, may have a ripple effect in the future. A paper slated to be published in the New England Journal of Medicine on November 7^th regarding the Phase II Iclusig Pace trial reportedly now requires modification in order to add toxicity and adverse event data following the FDA’s investigation. Even worse, those patients currently enrolled in an Iclusig clinical trial, or those taking the medication outside the trial may be faced with an agonizing decision: continue the drug which could potentially make the difference between a fatal disease and a chronic, but treatable disease, or stop taking the drug due to the high risk of negative health effects.